Accelerating the valorisation of the BEAT inflammation technology, a microbiome-based biotherapeutic for chronic respiratory inflammatory diseases.

BEAT inflammation
15 October 2020 → Ongoing
Regional and community funding: Industrial Research Fund
Research disciplines
  • Medical and health sciences
    • Medicinal products not elsewhere classified
Chronic lung disease beneficial bacteria anti-inflammatory probiotics live biotherapeutics inflammation
Project description

This project aims to increase the IP value and industrial partner attractiveness of the UGent BEAT technology, which offers an innovative approach to treat inflammation in patients with chronic lung disease. Although a scientific proof-of-concept has been established by the UGent research team, particular gaps remain to be addressed from an industry perspective. Hence, the proposed StarTT project aims to fill the gap between an academic and industry proof-of-concept.